Tokushima University / Educator and Researcher Directory --- Minato, Masanori

Search:

Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Internal Medicine ⟩ Nephrology ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada and Shu Wakino : Ability of NAD and Sirt1 to epigenetically suppress albuminuria., Clinical and Experimental Nephrology, Vol.28, No.7, 599-607, 2024. (Summary) The time for diabetic nephropathy (DN) to progress from mild to severe is long. Thus, methods to continuously repress DN are required to exert long-lasting effects mediated through epigenetic regulation. In this study, we demonstrated the ability of nicotinamide adenine dinucleotide (NAD) and its metabolites to reduce albuminuria through Sirt1- or Nampt-dependent epigenetic regulation. We previously reported that proximal tubular Sirt1 was lowered before glomerular Sirt1. Repressed glomerular Sirt1 was found to epigenetically elevate Claudin-1. In addition, we reported that proximal tubular Nampt deficiency epigenetically augmented TIMP-1 levels in Sirt6-mediated pathways, leading to type-IV collagen deposition and diabetic fibrosis. Altogether, we propose that the Sirt1/Claudin-1 axis may be crucial in the onset of albuminuria at the early stages of DN and that the Nampt/Sirt6/TIMP-1 axis promotes diabetic fibrosis in the middle to late stages of DN. Finally, administration of NMN, an NAD precursor, epigenetically potentiates the regression of the onset of DN to maintain Sirt1 and repress Claudin-1 in podocytes, suggesting the potential use of NAD metabolites as epigenetic medications for DN. (Keyword) Animals / Humans / Albuminuria / Claudin-1 / Cytokines / Diabetic Nephropathies / Epigenesis, Genetic / Fibrosis / Kidney Tubules, Proximal / Mice, Inbred C57BL / Mice, Knockout / NAD / Nicotinamide Mononucleotide / Nicotinamide Phosphoribosyltransferase / Podocytes / Sirtuin 1 / Sirtuins / Tissue Inhibitor of Metalloproteinase-1 (Tokushima University Institutional Repository) ● Metadata: 119528 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10157-024-02502-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38587753 ● Search Scopus @ Elsevier (PMID): 38587753 ● Search Scopus @ Elsevier (DOI): 10.1007/s10157-024-02502-w (Tokushima University Institutional Repository: 119528, DOI: 10.1007/s10157-024-02502-w, PubMed: 38587753)

Review, Commentary:

1.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Masanori Minato, Taizo Inagaki, 清水郁子, 山口純代, 宮上慎司, 多田美穂 and Shu Wakino : 特集糖尿病性腎症研究の最前線糖尿病性腎症の発症機序糖尿病性腎症におけるミトコンドリアの役割, Kidney and Dialysis, Vol.96, No.2, 159-164, Feb. 2024. (Link to Publication Site) ● Publication site (DOI): 10.24479/kd.0000001187 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390299528381041664 ● Search Scopus @ Elsevier (DOI): 10.24479/kd.0000001187 (DOI: 10.24479/kd.0000001187, CiNii: 1390299528381041664)

Proceeding of Domestic Conference:

1.	Shu Wakino, 柴田理恵子, Kazuhiro Hasegawa, Masanori Tamaki, Masanori Minato, Taizo Inagaki, 宮上慎司, 多田美穂 and Ichiro Hashimoto : 皮膚虚血・潰瘍病変患者における血中亜鉛濃度の意義, 第53回徳島透析療法研究会, Dec. 2023.
2.	Shu Wakino, Eriko Shibata, Masanori Minato, Ikuko Shimizu and Kazuhiro Hasegawa : 皮膚潰瘍病変患者における血中亜鉛濃度の意義, Journal of Japanese Society for Dialysis Therapy, Vol.56, No.Suppl.1, 566, May 2023.
3.	Masanori Minato, Ikuko Shimizu, Masanori Tamaki, Kazuhiro Hasegawa and Shu Wakino : 長時間のAPDにより至適透析を得た重度の精神発達遅滞を有する一例, Journal of Japanese Society for Dialysis Therapy, Vol.56, No.Suppl.1, 563, 2023.
4.	Masanori Tamaki, 宮上慎司, Ikuko Shimizu, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : ロキサデュスタット投与後に奇異性脳塞栓を発症した1例, Japanese Journal of Nephrology, Vol.64, No.6-W, 719, Oct. 2022.
5.	宮上慎司, Masanori Tamaki, Ikuko Shimizu, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : コロナウィルスワクチン後発症した悪性腎硬化症の一例, Japanese Journal of Nephrology, Vol.64, No.6-W, 719, Oct. 2022.
6.	Masanori Tamaki, 宮上慎司, Ikuko Shimizu, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Motoyuki Tamaki, Motoyuki Tamaki, Kazuhiro Hasegawa, Kojiro Nagai and Shu Wakino : ESAからロキサデュスタットへ切り替えた保存期CKD症例の解析, Japanese Journal of Nephrology, Vol.64, No.3, 257, May 2022.
7.	Sayo Ueda, Eriko Shibata, Masanori Tamaki, Masanori Minato, 岩城真帆, Ikuko Shimizu, 山口純代, 宮上慎司, Kazuhiro Hasegawa and Shu Wakino : 急性間質性腎炎を認めた敗血症性AKIの症例, Journal of Japanese Society for Dialysis Therapy, Vol.55, No.Suppl.1, 507, May 2022.
8.	Masanori Tamaki, 宮上慎司, 岩城真帆, Ikuko Shimizu, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Kojiro Nagai, Kazuhiro Hasegawa and Shu Wakino : 腹膜透析導入後に膵癌を発症した1例, Journal of Japanese Society for Dialysis Therapy, Vol.55, No.Suppl.1, 631, May 2022.
9.	Ikuko Shimizu, Masanori Tamaki, 宮上慎司, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : 慢性大動脈解離に伴う慢性DICのため腎代替療法導入に苦慮した1例, Journal of Japanese Society for Dialysis Therapy, Vol.55, No.Suppl.1, 663, May 2022.